Posts by Follicle Thought
Topical Cetirizine: The Complete Guide
Commissions we earn from partner links on this page do not affect our opinions or evaluations. Follicle Thought typically provides coverage on new hair loss treatments, but today we’re taking a slightly different approach. Many of our readers are using hair loss treatments, such as topical cetirizine, but it can be difficult to find all…
Read MoreAbbVie Shares Topline Results from Its Phase 3 Trial for Alopecia Areata
AbbVie has announced topline results for the second of its two Phase 3 clinical trials evaluating upadacitinib (RINVOQ) for alopecia areata. What is RINVOQ? The treatment is a prescription Janus kinase (JAK) inhibitor that is used to treat several conditions, like rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and atopic dermatitis. It is currently also being…
Read MoreUlo Debuts as the Latest Entrant in the Telehealth Hair Care Industry
Commissions we earn from partner links on this page do not affect our opinions or evaluations. This isn’t news about future treatments. Instead, this is about a new U.S.-based telehealth brand, Ulo, and its innovative prescription and over-the-counter treatments for hair growth. There are dozens of telehealth hair care brands, yet Follicle Thought has never…
Read MorePelage Pharmaceuticals Reports Phase 2a Results for Androgenic Alopecia
Pelage Pharmaceuticals has announced topline results from its Phase 2a trial of PP405, a new topical aimed at reactivating dormant hair follicle stem cells to treat androgenic alopecia (AGA). While the data show promise for a regenerative approach, there are important limitations and open questions to keep in mind. The Study The Phase 2a study…
Read MoreKintor Reports Results for KX-826 + Minoxidil Combo for Androgenic Alopecia
More news is coming out of Kintor Pharma this month. Kintor Pharma (HKEX: 9939) has announced that its observational study evaluating the combination of KX-826 and minoxidil for the treatment of androgenetic alopecia (AGA) in adult males in China has successfully reached its primary endpoint. This marks another milestone in the development of KX-826, following…
Read MoreInmagene Biopharmaceuticals Announces Positive Phase 2a Trial Results for IMG-007 in Alopecia Areata
Inmagene Biopharmaceuticals, a clinical-stage company focused on immunological and inflammatory diseases, has announced topline results from its Phase 2a clinical study of IMG-007 in patients with severe alopecia areata. What Is Inmagene Biopharmaceuticals? Inmagene Biopharmaceuticals was founded to advance therapies targeting immune-mediated and inflammatory conditions. The company develops novel monoclonal antibodies and small molecules, aiming…
Read MoreAtticus Pharma Initiates a First-in-Human Trial for Androgenic Alopecia Treatment ATC-002
Atticus Pharma, a clinical-stage biopharmaceutical company specializing in immunodermatology treatments, has announced the initiation of its first human clinical trial of ATC-002 for androgenic alopecia. What is Atticus Pharma? Atticus Pharma was founded in 2024 to develop pharmaceutical applications of its proprietary Z-pod® technology, a sustained-release drug delivery platform designed to improve treatment outcomes in…
Read MoreKintor Pharma’s Latest KX-826 Trial Reaches Its Primary Endpoint
Earlier this month, Kintor announced that its long-term Phase 3 safety trial of 0.5% KX-826 had reached its primary endpoint with statistically significant and clinically meaningful outcomes. This comes after a history of multiple trials, some with mixed results. The Trial This trial was a multi-center (16 centers), open-label study taking place over 52 weeks. …
Read MoreQ32 Bio Presents Data for Alopecia Areata Treatment at AAD 2025
Q32 Bio presented results from their SIGNAL-AA earlier this month at the American Academy of Dermatology (AAD) 2025 meeting for their novel alopecia areata (AA) therapy bempikibart. What is Bempikibart? Bempikibart is an experimental monoclonal antibody drug that targets two specific molecules in the body: the alpha receptor of interleukin-7 and the thymic stromal lymphopoietin…
Read MoreHCW Biologics Receive FDA Clearance For Alopecia Areata Trial
HCW Biologics has received FDA clearance to start a first-in-human safety trial for their potential alopecia areata treatment, HCW9302. Who Are HCW Biologics? HCW Biologics Inc. is a clinical-stage biopharmaceutical company based in Miramar, Florida. The company focuses on developing immunotherapies targeting chronic inflammation in age-related diseases like cancer, autoimmune disorders, and neurodegenerative conditions. The…
Read More